Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment
Public ClinicalTrials.gov record NCT00006164. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial (HALT-C)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The HALT-C Trial is a National Institute of Diabetes and Digestive and Kidney Diseases sponsored, randomized clinical trial of long-term use of Peginterferon alfa-2a (pegylated interferon) in patients who failed to respond to prior interferon treatment. All patients who enter the trial will be treated for 6 months with Peginterferon alfa-2a and Ribavirin. Patients who respond to this 6 month treatment will continue to be treated for an additional 6 months. Patients who do not respond to this treatment will be eligible for the long-term maintenance phase of this study where patients will be randomly selected to be treated with Peginterferon alfa-2a or to discontinue treatment for 3.5 years. Patients in both arms of this study will be followed closely with quarterly study visits. The combination of peginterferon plus ribavirin has recently been approved by the FDA for treatment of chronic hepatitis C. Patients who remain HCV-RNA positive after being treated for at least 6 months with peginterferon and ribavirin outside of this study may be eligible to directly enter the randomized portion of the HALT-C Trial. The HALT-C study is designed to determine if continuing interferon long-term over several years will suppress Hepatitis C virus, prevent progression to cirrhosis, prevent liver cancer and reduce the need for liver transplantation.
Study identification
- NCT ID
- NCT00006164
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,050 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2000 (Actual)
- Primary completion
- Apr 2007 (Actual)
- Completion
- Oct 2009 (Actual)
- Last update posted
- May 12, 2020
2000 – 2009
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California-Irvine/VA Medical Center-Long Beach | Long Beach | California | 90822 | — |
| USC School of Medicine | Los Angeles | California | 90033 | — |
| UCHSC (University of Colorado) | Denver | Colorado | 80262 | — |
| University of Connecticut Health Center | Farmington | Connecticut | 06030 | — |
| Lds, Niddk, Nih | Bethesda | Maryland | 20892-1800 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| UMass Memorial HealthCare, University Campus | Worcester | Massachusetts | 01655 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Saint Louis University | St Louis | Missouri | 63104 | — |
| University of Texas Southwestern - Dallas | Dallas | Texas | 75390-9195 | — |
| Medical College of Virginia | Richmond | Virginia | 23298-0341 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00006164, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 12, 2020 · Synced Oct 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00006164 live on ClinicalTrials.gov.